198 related articles for article (PubMed ID: 28735378)
1. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
[TBL] [Abstract][Full Text] [Related]
2. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
3. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
4. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
5. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
7. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
8. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
Tancredi R; Zambelli A; DaPrada GA; Fregoni V; Pavesi L; Riccardi A; Burdach S; Grohar PJ; D'Incalci M
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1317-20. PubMed ID: 25809543
[TBL] [Abstract][Full Text] [Related]
14. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
[TBL] [Abstract][Full Text] [Related]
15. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
16. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
18. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
[TBL] [Abstract][Full Text] [Related]
19. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
[TBL] [Abstract][Full Text] [Related]
20. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]